Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid E Fakkert

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Breast Cancer Research and Treatment|March 5, 2011
Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomyIngrid E Fakkert, Liesbeth Jansen, Kees Meijer, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 19, 2025
[Work-focused health care]Irene T M Lindenburg, Annelies E R C H Boonen, Ingrid E Fakkert, et al.
Familial Cancer|June 9, 2018
Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomyNatalia Teixeira, Marian J Mourits, Jan C Oosterwijk, et al.
International Journal of Cancer|June 9, 2020
Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndromeJanet R Vos, Ingrid E Fakkert, Liesbeth Spruijt, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 27, 2012
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation CarriersIngrid E Fakkert, Marian J E Mourits, Liesbeth Jansen, et al.
Plos One|January 7, 2017
Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian CancerIngrid E Fakkert, Eveline van der Veer, Elske Marije Abma, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancerIngrid E Fakkert, Elske Marije Abma, Iris G Westrik, et al.
Journal of the National Cancer Institute|May 12, 2019
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionJanet R Vos, Ingrid E Fakkert, Joanne A de Hullu, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Breast Cancer Research and Treatment|March 5, 2011
Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomyIngrid E Fakkert, Liesbeth Jansen, Kees Meijer, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 19, 2025
[Work-focused health care]Irene T M Lindenburg, Annelies E R C H Boonen, Ingrid E Fakkert, et al.
Familial Cancer|June 9, 2018
Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomyNatalia Teixeira, Marian J Mourits, Jan C Oosterwijk, et al.
International Journal of Cancer|June 9, 2020
Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndromeJanet R Vos, Ingrid E Fakkert, Liesbeth Spruijt, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 27, 2012
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation CarriersIngrid E Fakkert, Marian J E Mourits, Liesbeth Jansen, et al.
Plos One|January 7, 2017
Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian CancerIngrid E Fakkert, Eveline van der Veer, Elske Marije Abma, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancerIngrid E Fakkert, Elske Marije Abma, Iris G Westrik, et al.
Journal of the National Cancer Institute|May 12, 2019
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionJanet R Vos, Ingrid E Fakkert, Joanne A de Hullu, et al.
Pageof 1